Evidence map›Paper›PMID 37646078›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2023

Selective autophagy associated with iron overload aggravates non-alcoholic steatohepatitis via ferroptosis.

Koki Honma, Sora Kirihara, Hinako Nakayama, Taketo Fukuoka, Toshiaki Ohara, Kazuya Kitamori, Ikumi Sato, Satoshi Hirohata, Moe Fujii, Shusei Yamamoto and 2 more

Open access · greenAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 21 citations in OpenAlex.

  1. Crosstalk between autophagy and ferroptosis in liver diseases (Review).International journal of molecular medicine · 2026
    Review
  2. Review
  3. Observational
  4. Article
  5. Review
  6. Review
  7. Review
  8. Ferroptosis: biology and role in liver disease.Journal of gastroenterology · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. International journal of molecular sciences · 2024
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Koki HonmaDepartment of Medical Technology, Graduate School of Health Sciences, Okayama University, Okayama 700-8558, Japan.
Sora KiriharaDepartment of Medical Technology, Graduate School of Health Sciences, Okayama University, Okayama 700-8558, Japan.
Hinako NakayamaDepartment of Medical Technology, Graduate School of Health Sciences, Okayama University, Okayama 700-8558, Japan.
Taketo FukuokaDepartment of Medical Technology, Graduate School of Health Sciences, Okayama University, Okayama 700-8558, Japan.
Toshiaki OharaDepartment of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama University, Okayama 700-8558, Japan.
Kazuya KitamoriCollege of Human Life and Environment, Kinjo Gakuin University, Nagoya 463-8521, Japan.
Ikumi SatoAcademic Field of Health Science, Okayama University, Okayama 700-8558, Japan.
Satoshi HirohataAcademic Field of Health Science, Okayama University, Okayama 700-8558, Japan.
Moe FujiiDepartment of Medical Technology, Ehime Prefectural University of Health Sciences, Ehime 791-2101, Japan.
Shusei YamamotoDepartment of Medical Technology, Graduate School of Health Sciences, Okayama University, Okayama 700-8558, Japan.
Shang RanHeiLongjiang Provincial Center for disease control and prevention, Harbin 150030, China.
Shogo WatanabeAcademic Field of Health Science, Okayama University, Okayama 700-8558, Japan.ORCID 0000-0002-1700-2892
Okayama University · JPEhime Prefectural University of Health Science · JPHeilongjiang Center for Tuberculosis Control and Prevention · CNKinjo Gakuin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) that causes cirrhosis and hepatocellular carcinoma. Iron is an essential trace element in the body; however, excess iron can cause tissue damage and dysfunction. Iron overload is often observed in patients with NASH, and the amount of iron accumulated in the liver positively correlates with the histological severity of NASH. Ferroptosis, a novel form of iron-dependent cell death, is caused by the accumulation of lipid peroxidation and oxidative stress and is related to NASH. In addition, ferroptosis is closely related to autophagy, an intracellular self-degradation process. Although autophagy has many beneficial effects, it may also be harmful to the organism, for example, inducing ferroptosis. It is unclear whether iron overload aggravates NASH via autophagy. The aim of this research is to determine the mechanism by which iron overload induces ferroptosis via autophagy and aggravates NASH. Stroke-prone spontaneously hypertensive rats (SHRSP5/Dmcr) were divided into two groups and fed a high-fat and high-cholesterol (HFC) diet for eight weeks. Iron dextran was administered to the Fe group in addition to the HFC diet. Blood analysis, histological staining, calcineurin activity assay, quantitative reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence staining, and electron microscopy were performed. The results showed that iron overload promoted autophagy via nuclear translocation of transcription factor EB (TFEB) and induced ferritinophagy, which is the autophagic degradation of ferritin. In addition, the HFC diet induced lipophagy, the autophagic degradation of lipid droplets. The Fe group also exhibited promoted ferroptosis and aggravated hepatic inflammation and fibrosis. In conclusion, iron overload accelerates ferritinophagy and lipophagy, aggravating NASH pathology via ferroptosis. These findings indicate the therapeutic potential of inhibiting autophagy and ferroptosis for treating NASH.

Indexed as

FerroptosisIron OverloadLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseAnimalsAutophagyFibrosisHumansIronRatsRats, Inbred SHRIronautophagyferritinophagyferroptosisiron overloadlipophagyNon-alcoholic steatohepatitis

Identifiers

PMID37646078
PMCPMC10583757
OpenAlexW4386272444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.